Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
OCUP similar filings
- 27 Nov 23 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
- 13 Nov 23 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
- 2 Nov 23 Ocuphire Corporate Presentation November 2023
- 1 Nov 23 Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
- 27 Sep 23 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
- 11 Aug 23 Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
- 1 Aug 23 Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
Filing view
External links
Exhibit 10.3
FIRST AMENDMENT TO
OCUPHIRE PHARMA, INC.
2021 INDUCEMENT PLAN
The Ocuphire Pharma, Inc. 2021 Inducement Plan (the “Plan”) is hereby amended in the following respects, effective November 1, 2023, in accordance with Section 2(b)(vi) of the Plan.
The first sentence of Section 3(a) of the Plan is deleted in its entirety and replaced with the following sentence:
“Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 2,325,258 shares (the “Share Reserve”).”